Recordati Rare Diseases, Inc.
Recordati Rare Diseases, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2011, the company has rapidly established itself as a leader in developing and commercialising innovative treatments for rare diseases, focusing on areas such as metabolic disorders and genetic conditions. With a portfolio that includes unique therapies tailored to meet the needs of patients with rare conditions, Recordati Rare Diseases stands out for its commitment to addressing unmet medical needs. The company has achieved significant milestones, including strategic partnerships and the successful launch of several key products that have positively impacted patient lives. Recognised for its dedication to rare disease research, Recordati Rare Diseases continues to strengthen its market position through ongoing innovation and patient-centric initiatives.
DitchCarbon Score
How does Recordati Rare Diseases, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Recordati Rare Diseases, Inc.'s score of 55 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Recordati Rare Diseases, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Recordati Industria Chimica e Farmaceutica S.p.A., which is responsible for cascading emissions data and climate commitments. As of now, there are no documented reduction targets or climate pledges specific to Recordati Rare Diseases, Inc. However, it inherits its climate initiatives from its parent company, Recordati Industria Chimica e Farmaceutica S.p.A., which may have established targets and commitments at a higher corporate level. Given the absence of specific emissions data and reduction initiatives for Recordati Rare Diseases, Inc., it is essential to monitor updates from its parent organisation for any future commitments or achievements in carbon emissions reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 27,785,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 10,302,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Recordati Rare Diseases, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
